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• Discuss common pump 
errors 
• Review titratable drips 
– Mechanism of Action (MOA) 
– Indication 
– Starting and max rates 
– Adverse effects 
– Monitoring 
• Focus on heparin protocol 
• Practice a calculation 
• Apply to a patient case 
 




– Analgesics: opioids 
– Sedatives 








• Definition of titration 
• Check vital signs every 15 min when 
actively titrating 
• No IV drips may be run as an IVPB 
• Choose CCA: ICU/IMC-card (or ICU-gen) 
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Common Pump Errors 
• Choosing the 
wrong drug/conc. 
from the library 
(verify drip conc. 
matches pump 
conc.) 
• Entering the 
wrong pt weight 
• Choosing “Drug 
not in Library” 
and entering the 
wrong 
concentration 











General Guidelines for Pressors 
 
• Treat hypovolemia induced hypotension with 
fluids PRIOR TO giving vasopressors  
• Titrate one pressor at a time 
• Central line 
– Monitor infusion site for extravasation  
– Antidote: phentolamine (an alpha-receptor antagonist) 
intradermally 
• DO NOT administer sodium bicarbonate in the 
same line as any vasopressor (incompatible). 
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Common Adverse Effects of Pressors 
• Hypoperfusion (skin, kidneys, GI tract, etc), 
dysrhythmias, myocardial ischemia 
• Warning: high doses can result in peripheral and 
mesenteric ischemia leading to digit loss and bowel 
necrosis  
• If you are close to the max rate, it is time to add another 
pressor. Do NOT continue to increase the rate. 
7 
Receptors 
Receptor Site Action 
Alpha-1 (α1) Smooth muscle (vascular, 
sphincters) 
Smooth muscle contraction, 
vasoconstriction  
Alpha-2 (α2) CNS Inhibits norepinephrine 
release  
↓HR, ↓BP  
Beta-1 (ß1) Heart ↑contractility (inotrope), ↑ HR 
(chronotrope), ↑automaticity, 
↑ conduction velocity  
Beta-2 (ß2) Smooth muscle (vascular, 
bronchioles, intestine) 
Vasodilation 
Dopaminergic (D) Vascular smooth muscle (renal, 
mesenteric, coronary) 
Vasodilation  
Vasopressin (V1, V2) Kidney ↑ free water retention, ↑ 




Drug Dose Range Receptor Effect 
Dopamine (Intropin®)  1-5 mcg/kg/min 
5-10 mcg/kg/min 
10-20 mcg/kg/min  
D>ß2> ß1 
ß1, ß2>D> α1 
α1> ß1, ß2>>D  
Increase HR, 




0.05-1 mcg/kg/min  
ß1, ß2 >> α1 
ß1 > α1, ß2  
↑↑HR, ↑contractility, 
↓SVR↑ HR, 
↑contractility, ↑SVR  
Norepinephrine 
(Levophed®)  








40-180 mcg/min  α1 ↑↑SVR  
Vasopressin 
(Pitressin®)  
0.01-0.04 units/min  
2-4 units/hour 




• Potent alpha-1 agonist activity, weak beta-1 activity 
(may see ↑ HR)  
• First line vasopressor for septic shock (after fluids). 
Can also be used for other types of shock. 
• WATCH for decreased cardiac output, reflex 
bradycardia, and chest pain or ventricular arrhythmias 
 
Concentration  4 mg/250 mL (DS 8 mg/250 mL, QS 16 mg/250 mL) 
May be mixed in the ICU in an emergency 
Starting Dose  0.01 mcg/kg/min (or 8 mcg/min) 
Titration  Increase by 0.05 mcg/kg/min every 1 minute to 
maintain SBP greater than 90 mmHg (or as 
ordered)  




• Other name: antidiuretic hormone (ADH) 
• MOA: stimulates vasopressin receptor  vasoconstriction 
and free water retention (no inotropic or chronotropic 
effects) 
• Indication:  
– Second agent to add in septic shock  (add to norepinephrine) 
– Post-CABG 
– Not a stand-alone agent   
• Watch for arrhythmia, asystole, or ↓ CO 
Concentration  100 units/100 mL 
Usual rate 2-4 units/hour 
Titration  Fixed rate (not titrated). 
Maximum Rate  6 units/hour 
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EPINEPHrine (Adrenalin®) 
• Has almost equal alpha-1, beta-1, and beta-2 agonist 
activity (↑ HR, CO, SV, and SVR)  
• Indication:  
– Septic shock: preferred agent to add to norepi + vasopressin 
– Bradycardia, anaphylactic shock, cardiac arrest, post-CABG 
• WATCH for HTN, dysrhythmias, tachycardia, 
hyperglycemia 
Concentration  1 mg/250 mL (DS 2 mg/250 mL, QS 4 mg/250 mL) 
May be mixed in the ICU in an emergency 
Starting Dose  0.01 mcg/kg/min  
Titration  Increase by 0.05 mcg/kg/min every 1 minute to 
maintain SBP greater than 90 mmHg (or as 
ordered) 





– Hypotension or symptomatic bradycardia 
– No longer recommended in septic shock 
• DO NOT USE in patients with 
– Uncorrected tachyarrhythmias 
– Ventricular fibrillation 
Concentration  Premix 800 mg/500 mL (DS 800 mg/250 mL) 
Starting Dose  5 mcg/kg/min  
Titration  Increase by 1-4 mcg/kg/min every 10 minutes 
Dose dependent effects: 
5-10 mcg/kg/min (cardiac dosing/β1 receptors): increased renal blood flow,   HR, 
cardiac contractility, cardiac output 
>10 mcg/kg/min (vasopressor dosing/α1 receptors) : vasoconstriction, increased 
blood pressure, HR  
Maximum Rate  20 mcg/kg/min  (greater doses may not improve BP but may increase arrhythmias) 
Dopamine 
– No “renal dose” of dopamine 
• Low doses will increase UOP but do NOT improve or 
protect renal function  
– Adverse effects 
• Common vasopressor ADRs, but especially tachycardia, 
tachyarrhythmias, and angina 
• These hamper clinical use and are more common with 
higher doses. 
• Studies have shown an increased mortality due to 
tachyarrhythmias in septic shock, and this is why 
dopamine is no longer recommended in septic shock (only 




PHENYLephrine (Neosynephrine®)  
• Acts as a pure alpha-1 agonist ONLY 
• Indication:  
– Hypotension in patients with tachyarrhythmias (afib) since no B1 effects 
– Not recommended in septic shock Use as a second or third-line therapy to 
treat hypotension from shock resistant to other vasopressor agents (salvage 
therapy). 
• Use extreme caution in HF or cardiogenic shock; ↑ SVR may 
significantly ↓ CO 
• WATCH for ↓ CO, reflex bradycardia, severe peripheral and visceral 
vasoconstriction 
Concentration  60 mg/100 mL 
Starting Dose  100-180 mcg/min until BP stabilized 
Titration  Increase by 10 mcg/min every 1 minute to maintain SBP > 
90.  Once BP stabilized, decrease to 40-60 mcg/min 
Maximum Rate  180 mcg/min  
           















• LT is a 78 year old man who presents to ER with 
AMS, SOB, cough with yellow sputum, and fever 
from a nursing home. He is diagnosed with 
sepsis secondary to HCAP.   
• PMH: COPD, DM2, HTN 
• VS: P 102    BP 78/34  RR 30  T 38.4 °C 
• What is the first intervention you would recommend for 
the BP? 
• After the intervention, BP is 83/42.  What is your next 
recommendation? 
• BP is 88/44.  What now? 
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INOTROPES 
Recall that ionotropic refers to increased strength of 
contraction of heart muscle   increased cardiac 




• Potent beta-1 agonist: strong positive ionotropic activity 
• Some beta-2 and alpha agonist activity. Because of  B-2 activity, dobutamine 
does not cause vasoconstriction and may ↓ BP 
• Indications 
– Septic shock: pts with low CO and high filling pressures (CI < 3 L/min/m2 
or ScVO2 < 70%) 
– Cardiogenic shock.  Vasopressors may need to be given to counteract 
arterial vasodilation.   
• WATCH for:  hypotension, hypertension, arrhythmias 
19 
Concentration Premix 250 mg/250 mL  
(DS 500 mg/250 mL, QS 1000 mg/250 mL) 
Starting dose 5 mcg/kg/min 
Titration Gradually adjust rate at 2-10 minute intervals 
according to Cardiac Index (CI) goal 
Max Rate 20 mcg/kg/min (40 mcg/kg/min) 
Milrinone (Primacor®) 
• MOA: inotrope (phosphodiesterase-3 inhibitor) 
– Dose-dependent  VD can ↑ CO through SVR reduction 
– Lowering of PAP  beneficial in patients with pulmonary congestion due to LV 
dysfunction (pulmonary hypertension).  
• Indication: acute decompensated heart failure, post-CABG, ↑ PAP 
• Typical 1-3 hour delay in hemodynamic effects 
• Rate requires adjustment for renal impairment 
• WATCH for: arrhythmias, hypotension (esp. with LD), hepatotoxicity 
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Concentration Premix 40 mg/200 mL 
Maintenance dose 0.375-0.75 mcg/kg/min 
50 mcg/kg loading dose over 10 min optional, 
hypotension likely 
Titration Titrate by 0.2 mcg/kg/min every 30 minutes to goal CI 
Max Rate 0.75 mcg/kg/min 
11 
Application 
• LT’s BP is being maintained on two 
pressors.  However, his ScVO2 is 65%.  
You check his hemoglobin and it is 9 g/dL. 








• Regular ONLY 
• Indications: 
– DKA / HHNK 
– Post-op hearts 
– High doses of epinephrine infusions  
• Flush with 20 mL to minimize adsorption to IV tubing 
• Monitoring: goal BG 100-159.  Check FSBS initially every hour 
• Powerplans:  
– Protocol Hyperglycemia  Management (XY) 
– Protocol Intensive Insulin Infusion 
– ENDO DKA PowerPlan 
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Concentration 100 units/100 mL 
Starting rate 1-10 units/hour, depending on protocol severity 
ordered 
Titration Per protocol 
Max rate Per protocol.  Notify provider if rate > 40 units/hr 
Application 
• LT’s blood glucose ranges from 190-280 
mg/dL. 
• What recommendation would you make to 
the physician? 
• What medication is LT receiving that could 
















- ↑ myocardial O2   
  consumption 
Respiratory Effects 
- Shallow breathing 
- Tachypnea 




Muscle breakdown,  
poor wound healing 
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Anxiety, Pain, Delirium 
Underlying Medical 
Conditions 





























Agitation Pain, Anxiety 
Calm/alert 







• Assess pain regularly 
• Treatment 
– Nonpharmacological 
• Positioning of patient 
• Positioning of ventilator and feeding tubes 
• Heat or cold therapy 
– Pharmacological 
• Opioids (most common in ICU) 






– Most rapid onset, shortest 
duration 
• Preferred in acutely 
distressed pts 
• Preferred in short procedures 
– Accumulation and prolonged 
effects in repeated dosing  
• Morphine 
– Longer duration, intermittent 
doses may be given 
– Active metabolite: prolonged in 
renal insufficiency 
– Histamine release 
– Hypotension may result 
 
• Hydromorphone 
– Duration similar to morphine 
– Lacks active metabolite or 
histamine release 
– Confused with morphine but is 
~7 times stronger than morphine! 
• Meperidine 
• Avoid due to potential for 
neurotoxicity 
• Normeperidine causes 
neuroexcitation (apprehension, 
tremors, delirium, seizures)  
• Interact with antidepressants (can 
cause serotonin syndrome) 
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Analgesic Administration 
• Preventing pain is more effective than treating established 
pain 
• Administer on a scheduled or scheduled intermittent basis  
+ PRN doses 
• Patient Controlled Analgesia (PCA) 
• Continuous Infusion- done through the PCA pumps at ISMC 
• PRN only not as effective 
• Monitor for respiratory depression, constipation (schedule 










• Sedate agitated patients only after adequate 
analgesia and treatment of reversible causes  
• 2002 SCCM Sedation Guidelines 
– Midazolam only for short-term sedation (< 2 days) 
– Lorazepam for long-term sedation (> 3 days) 
– Propofol for patients requiring intermittent awakenings 
• 2013 version non-benzodiazepine sedatives 







Richmond Agitation Sedation Scale (RASS) 
+4 Combative 
+3 Very agitated 
+2 Agitated 
+1 Restless 
0 Alert and calm 
-1 Drowsy 
-2 Light sedation 
-3 Moderate sedation 
-4 Deep sedation 
-5 Unarousable 
Propofol (Diprivan®) 
• MOA: general anesthetic for sedation 
• Shortest acting sedative (duration 10-15 min; 
accumulates over time 
• Contraindications: egg allergy, no MV 
• Administration 
– Vented tubing 
– Dedicated line (potential incompatibility and infection) 
– Strict aseptic technique must be used due to a high infection 
risk. Tubing and vial MUST be changed every 12 hours 
• Green urine is rare but may  






• WATCH for:  
– Hypotension (especially after bolus dosing) 
– Bradycardia 
– Respiratory depression or apnea 
– Pancreatitis- monitor triglycerides 
– Propofol-related infusion syndrome (PRIS) 
• Risk increases with increasing dose and duration 
• Syndrome of lactic acidosis, bradycardia, hyperlipidemia, and 
rhabdomyolysis 








1000 mg/100 mL premixed and undiluted  
Bolus Dose NURSING CANNOT BOLUS DOSE    
Starting Dose 5 mcg/kg/min 
Titration 
May increase by 5-10 mcg/kg/min every 5 minutes until at 
target sedation 
Weaning 
Decrease by 5-10 mcg/kg/min every 5 minutes. Abrupt 
discontinuation associated with anxiety, agitation, and 
resistance to mechanical ventilation. 
Maximum 
Infusion Rate 
50 mcg/kg/min (physician’s order required for higher rates) 
36 
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Y-site Compatibility with Propofol 
37 
Drug Y-site Compatible? 
Amiodarone (Cordarone®) NO 
Diltiazem (Cardizem®) NO 
Dobutamine (Dobutrex®) Yes 
Dopamine Yes 
Epinephrine (Adrenalin®) Yes 
Eptifibatide (Integrilin®) NO 





Midazolam (Versed®) NO 
Morphine  Yes 
Nicardipine (Cardene®) NO 
Nitroglycerin  Yes 
Nitroprusside (Nipride®) NO 
Norepinephrine (Levophed®) Yes 
Phenylephrine (Neosynephrine®) NO 




• MOA: binds to benzodiazepine receptors 
• Indication: sedation  
• Factors affecting intensity and duration of effect  
– Delayed emergence from sedation with prolonged administration (due to 
saturation of tissues) in elderly patients, hepatic dysfunction (all BZDs are 
metabolized by the liver), or renal insufficiency  
– Prior alcohol abuse and concurrent drug therapy may increase the dosages 
required  
• Adverse effects 
– Respiratory depression and hypotension, especially when given with opioids  
– May also contribute to delirium  
– Potential for accumulation  
• Reversal: flumazenil (Romazicon®) not recommended 
– Risk of inducing withdrawal after prolonged therapy  
– Reversal of patients on BZD for seizures or increased intracranial pressure could 






• Used most often for procedures requiring moderate 
sedation as IVP 
• Rapid onset, short duration of action with single doses 
(useful for acute agitation) 
• Accumulation and prolonged sedation due to active 




Concentration  100 mg/100 mL 
Starting rate 1 mg/hr 
Titration Titrate by 2 mg/hr every 10 minutes to goal RASS 
Max rate 10 mg/hr 
Lorazepam (Ativan®) 
• Slightly slower onset than midazolam, less useful for acute 
agitation  
• Infusion is not readily titratable due to half life of ~8 hours  
• Commonly used to treat alcohol withdrawal and seizures 
• Solvent is propylene glycol. May cause reversible acute 
tubular necrosis, lactic acidosis, and hyperosmolar states  
40 
Concentration  40 mg/50 mL 
Starting rate 1 mg/hr 
Titration Titrate by 2 mg/hr every 10 minutes to goal RASS 
Max rate 10 mg/hr 
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Dexmedetomidine (Precedex®) 
• MOA: selective α2-agonist sedative, small  
analgesic properties 
• Patients remain sedated when undisturbed, but 
arouse readily---does not work well as 
monotherapy for sedation 
• Indication 
– Short-term sedation of mechanically ventilated 
patients with anticipated early extubation 





• ADRs: hypotension (24-56%), hypertension with bolus 
doses, bradycardia (5-42%), can be severe 
• Caution with vasodilators or drugs that ↓ HR 
• Expensive: 3x propofol 
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Concentration  200 mcg/50 mL 
Starting rate 0.2 mcg/kg/hr 
Optional loading dose: 1 mcg/kg over 10 min (omit if 
concern for hemodynamic compromise) 
Titration 0.1 mcg/kg/hr every 15 minutes to RASS of 0 to -2.  Allow 
15 minutes for peak effect after each dosage change. 
Abrupt discontinuation should be avoided (nervousness, 
agitation, HA, rapid ↑ BP). 









• NMBAs have NO analgesic or amnestic effects 
• Patients may appear comfortable, but analgesia and 
sedation MUST BE USED 
• Indications 
– All other modalities must be tried first- NMBAs should be a last resort 
– Facilitate mechanical ventilation: used for both rapid sequence 
intubation (RSI) and ventilator asynchrony 
– Acute respiratory distress syndrome (ARDS) 










• Paralysis: Peripheral Nerve Stimulator (2:4)  
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Sedation Level BIS value Level of Consciousness 
  0 Flat line EEG, absence of brain activity 
Deep Sedation 20-40 Burst suppression 
Deep Sedation 40-60 
Low probability of explicit recall Unresponsive 




Responds to loud commands or mild 
prodding/shaking 
Anxiolysis 80-90 Responds to normal voice 
Anxiolysis 90-100 Awake 
NMBA Checklist 
Before starting a NMBA make sure: 
Scheduled or continuous analgesia 
Scheduled or continuous sedation 
DVT prophylaxis 
Stress ulcer prophylaxis 
Eye drops or ointment 





• Most common paralytic infusion at ISMC 
• Metabolism not affected by renal or 
hepatic disease 
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Concentration 200 mg/100 mL 
Starting rate 0.5 mcg/kg/min 
Titration Titrate by 1 mcg/kg/min every 10 minutes to goal 
train-of-four of 2:4 
Max rate 10 mcg/kg/min 
Rapid Sequence Intubation (RSI) 
– Definition: using a sedative (often etomidate) along with a NMBA 
to quickly achieve readiness for endotracheal intubation 
– Associated with an improvement in intubating conditions and 
reduction in hypoxemia and complications (aspiration, traumatic 
intubation, dental injury) 
• Succinylcholine: 
– 1-1.5 mg/kg once (~100 mg in a 70 kg adult) 
– Avoid  when depolarizing effect can cause increase in extracellular potassium 
(sustained muscle weakness, prolonged immobility, renal failure) 
• Rocuronium: 
–  1-1.2 mg/kg once 
– Used in RSI when succinylcholine is contraindicated  
– Duration much longer than succinylcholine (60-80 min); may not be 





• LT continues to decline and develops 
respiratory failure and ARDS as a 
complication of HCAP/sepsis.  His SCr is 
3.4. The pulmonologist wants to start a 
paralytic.   
• Which paralytic would you recommend 










• MOA: non-dihydropyridine CCB 
• Indications: 
– Lower the ventricular response in A-fib, Atrial flutter, and SVT 




Concentration 125 mg/125 mL 
Bolus dose A bolus dose of 0.25 mg/kg (in adults usually 10-20 mg) may be 
given over 2 minutes.  May be repeated once at 0.35 mg/kg after 
15 minutes.    
Starting dose 5-10 mg/hr 
Titration Titrate by 5 mg/hr every 15 minutes up to 15 mg/hr 
Max Rate 15 mg/hr 
Amiodarone 
• MOA: class III antiarrhythmic agent that slows intra-cardiac conduction.   
• Indication: 
– Ventricular arrhythmias (VT, Vfib) 
– Rapid ventricular rates associated with SVT, Afib  
– Conversion from atrial fibrillation RVR (particularly if little response to BB or 
CCB) 
• 0.22 micron filter required 
• Infuse through dedicated IV line (central preferred) 
• Contraindication: 2nd or 3rd degree AV heart block, bradycardia, cardiogenic 
shock 




  Usual Concentration Rate (mg/min) Rate (mL/hr) 
Loading Dose 150 mg/ 100 mL D5W  15 mg/min 
600 mL/hr for 10 
minutes 
Slow Loading Dose 450 mg/250 mL D5W 1 mg/min 33.3 mL/hr for 6 hours 
Maintenance Dose 450 mg/250 mL D5W  0.5 mg/min 




• MOA: short acting β1-selective beta-blocker 
• Indication: SVT, HTN, atrial fibrillation/flutter 
• Contraindication: HF, cardiogenic shock, bradycardia, 
2nd or 3rd degree heart block, hypotension 
• WATCH for: bradycardia and hypotension 
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Concentration 2500 mg/250 mL (DS 2000 mg/100 mL) 
Bolus dose 500 mcg/kg loading dose over 1 minute. Loading dose may be 
repeated up to three times per physician order. 
Starting dose 50 mcg/kg/min 
Titration Titrate by 50 mcg/kg/min every 4 minutes to patient response 
Weaning Decrease the infusion rate in increments to 25 mcg/kg/min after 
therapeutic dose has been reached 
Max Rate 200 mcg/kg/min 
Application 
• LT is improving due to his excellent care 
and is able to come off all his IV drips 
except for norepinephrine. You notice that 
his HR is 128 with irregularly irregular R-R 
and no p waves. 









• MOA: dihydropyridine calcium channel blocker 
• Indication: antihypertensive, HTN crisis, ischemic stroke 
• Contraindication: aortic stenosis (may ↓ coronary perfusion → ischemia)   
• Peripheral or central line 




Concentration 50 mg/250 mL 
Starting dose 5 mg/hr 
Titration Titrate by 2.5 mg/hr every 15 minutes to patient response.   
Do not abruptly discontinue.  Abrupt withdrawal may cause rebound 
angina in patients with CAD.  
Max Rate 15 mg/hr 
29 
Nitroprusside (Nipride®) 
• MOA: direct vasodilator potent arterial vasodilator 
• Indications: usually LAST OPTION for hypertensive crisis, ischemic stroke, HF, post-CABG 
• Cyanide toxicity at high infusion rates for long periods of time.  Use with caution in hepatic 
or renal impairment 
• Light sensitive: keep drug and tubing covered 
• WATCH for:  
– Excessive hypotension: do not leave the bedside while titrating. Sudden and extreme decreases 
in systolic blood pressure have been associated with this infusion. Monitor BP every 5 minutes 
during titration. 
– Cyanide toxicity: monitor for cyanide toxicity via metabolic acidosis and SVO2 
• Initial symptoms: flushing, tachycardia, tachypnea, headache, and dizziness.  
• Worsening toxicity: loss of consciousness, coma, hemodynamic compromise, arrhythmias, seizures, apnea, 
cardiac arrest, and death. 
– Thiocyanate toxicity: in renal impairment, prolonged infusion (>3 days), dose ≥4 mcg/kg/ minute 
– Headache, Nausea 
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Concentration 50 mg/250 mL . May be mixed in the ICU in an emergency 
Starting dose 0.3 mcg/kg/min 
Titration Increase by 0.5 mcg/kg/min every 3-5 minutes to effect or until headache/nausea occurs 
Max Rate 10 mcg/kg/min (rarely need greater than 4 mcg/kg/min).   
When administered by prolonged infusion faster than 2 mcg/kg/minute, cyanide is generated 
faster than an unaided patient can handle. 
Nitroglycerin 
• MOA: coronary vasodilator and peripheral venodilator (reduces 
preload) 
• Indication: angina, hypertension, CHF, and pulmonary hypertension 
• Contraindications:  
– Head trauma or ICH 
– Within 24 hours of sildenafil (Viagra®) or vardenafil (Levitra®) or within 48 hours 
of tadalafil (Cialis®).  May cause severe hypotension, MI, or death 
• WATCH for: 
– Hypotension 
– Lightheadedness, headache (common) 
– Tachycardia  
– Flushing of the face and neck  
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Concentration Premix 50 mg/250 mL 
Starting dose 5 mcg/min IV 
Titration Increase by 5 mcg/min every 3-5 minutes to 20 mcg/min.  If no response at 20 mcg/min, 
increase by 10 mcg/min every 3-5 minutes. 
Max Rate 200 mcg/min 
30 
Application 
• Two weeks later LT was discharged to 
LTAC, but he returns to the ER after one 
week with crushing chest pain and BP 
240/172.  The plan is to go to the cath lab. 
• In the meantime, what is your 
recommendation for his BP? 
• What are your HTN recommendations 















• MOA: Potentiates antithrombin III and inactivates thrombin 
• Indication: anticoagulant for DVT/PE or in ACS 
• Monitor: HPTT 6 hours after initiation and each rate 
change (keep 42-70), S/S bleeding, H/H 
• Antidote: protamine sulfate 
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DVT/PE ACS 
Concentration Premix 25,000 units/500 mL 
Loading Dose 80 units/kg (round to nearest 100 
units), max 10,000 units 
60 units/kg, round to nearest 
100 units, max 4000 units 
Maintenance 
dose 
18 units/kg/hr  
(round to nearest 50 units), not to 
exceed 1500 units/hr 
12 units/kg/hr 
(round to nearest 50 units), max 
1000 units/hr 
Titration Per protocol 












• Pharmacist calculates and enters patient specific doses in order comments 
• Bolus dose and rates vary based on HPTT, patient weight, and protocol (VTE vs. ACS) 
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Heparin for VTE: titration for 70 kg patient 
HPTT < 32             5600 unit bolus and INCrease infusion BY 300 units/hour 
HPTT 32 - <35       4200 unit bolus and INCrease infusion BY 200 units/hour 
HPTT 35 - 40         2800 unit bolus and INCrease infusion BY 150 units/hour 
HPTT 40 - 41         NO bolus; INCrease infusion BY 50 units/hour 
HPTT 42 - 70         NO CHANGE;  Recheck HPTT in 6 hrs. After two that result in no                                
.                              rate change, order HPTT next morning   
HPTT 71 - 75         NO bolus; DECrease infusion BY 50 units/hour 
HPTT 76 - 85         NO bolus; DECrease infusion BY 100 units/hour 
HPTT 86 - 90         NO bolus; DECrease infusion BY 150 units/hour 
HPTT 91 - 110       HOLD INF x 1 hr, then resume at rate lower BY  200 units/hour 
HPTT > 110           HOLD INF and notify physician promptly    
Heparin for ACS: titration for 70 kg patient 
HPTT < 32             4000 unit bolus and INCrease infusion BY 200 units/hour 
HPTT 32 - <35       3500 unit bolus and INCrease infusion BY 150 units/hour 
HPTT 35 - 41         2800 unit bolus and INCrease infusion BY 100 units/hour 
HPTT 42 - 70         NO CHANGE;  Recheck HPTT in 6 hrs. After two that result in no                                
.                              rate change, order HPTT next morning   
HPTT 71 - 78         NO bolus; DECrease infusion BY 50 units/hour 
HPTT 79 - 85         NO bolus; DECrease infusion BY 100 units/hour 
HPTT 86 - 90         NO bolus; DECrease infusion BY 100 units/hour 
HPTT 91 - 110       HOLD INF x 1 hr, then resume at rate lower BY  200 units/hour 
HPTT 111 - 155    HOLD INF x 90 min, then resume at a rate lower BY  200 units/hour 
HPTT > 155           HOLD INF x 90 min, then resume at a rate lower BY  300 units/hour 
Titration 






What is HPTT? 
Stat labs 
Daily labs 
Nurse ordered HPTT per protocol 
Please make sure to check labs q 6 hours until you reach NO Change X 2 
then you may change to q day HPTT 
HPTT Labels 
• If more than one HPTT is ordered at a 
time, ensure that the time on the label 
matches the time the level was drawn. 
– Levels have been reported at the wrong time 
due to label mismatch.  
– This can cause patient harm by leading to 




How to document rate changes on the MAR  
• Go to heparin order (Modify heparin order) 
• Change unit rate to desired units per hour per protocol 














• Document as rate change in the MAR  
72 
Holding Infusion due to HPTT 
 
• If HPTT 91 – 110, the order states to “HOLD INFUSION x 1 hr, then resume at 
a rate lower BY 200 units/hour” 
• Document as rate change to zero and add comment about holding dose x 1 hr 
• After holding for one hour, document rate change with new infusion rate.  




How to document bolus on the MAR 





• Scan your heparin and document units given per protocol. 
Heparin Titration Problem 
• WZ is on a heparin drip at 1300 units/hr.  The 24 hour 
HPTT is 33.  What should you do? 
74 
HPTT < 32             5600 unit bolus and INCrease infusion BY 300 units/hour 
HPTT 32 - <35       4200 unit bolus and INCrease infusion BY 200 units/hour 
HPTT 35 - 40         2800 unit bolus and INCrease infusion BY 150 units/hour 
HPTT 40 - 41         NO bolus; INCrease infusion BY 50 units/hour 
HPTT 42 - 70         NO CHANGE;  Recheck HPTT in 6 hrs. After two that result in no                                
.                              rate change, order HPTT next morning.  
HPTT 71 - 75         NO bolus; DECrease infusion BY 50 units/hour 
HPTT 76 - 85         NO bolus; DECrease infusion BY 100 units/hour 
HPTT 86 - 90         NO bolus; DECrease infusion BY 150 units/hour 
HPTT 91 - 110       HOLD INF x 1 hr, then resume at rate lower BY  200 units/hour 
HPTT > 110           HOLD INF and notify physician promptly    
• Bolus 4200 units, document in MAR  
• Modify order per protocol and increase infusion to 1500 
units/hr. 
• Order HPTT 6h after rate change. 
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Heparin Titration Problem 
• HPTT rechecked after 6 hours is 45. The current rate is 
1500 units/hr. What should you do? 
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HPTT < 32             5600 unit bolus and INCrease infusion BY 300 units/hour 
HPTT 32 - <35       4200 unit bolus and INCrease infusion BY 200 units/hour 
HPTT 35 - 40         2800 unit bolus and INCrease infusion BY 150 units/hour 
HPTT 40 - 41         NO bolus; INCrease infusion BY 50 units/hour 
HPTT 42 - 70         NO CHANGE;  Recheck HPTT in 6 hrs. After two that result in no                                
.                              rate change, order HPTT next morning.  
HPTT 71 - 75         NO bolus; DECrease infusion BY 50 units/hour 
HPTT 76 - 85         NO bolus; DECrease infusion BY 100 units/hour 
HPTT 86 - 90         NO bolus; DECrease infusion BY 150 units/hour 
HPTT 91 - 110       HOLD INF x 1 hr, then resume at rate lower BY  200 units/hour 
HPTT > 110           HOLD INF and notify physician promptly    
• No change in rate 
• Order new 6 hr HPTT.  If level is 42-70, NO CHANGE 








• MOA: direct thrombin inhibitor 
• Indication: anticoagulant for ACS, HIT 
• Target aPTT 42-70 seconds, check 2 hours after 





Concentration 250 mg/500 mL 
Bolus 0.75 mg/kg x 1  prior to PCI None 
Starting dose 1.75 mg/kg/hr during procedure and 4 
hours after procedure 
May be continued up to 10 hours after 
procedure at 0.2 mg/kg/hr 
CrCl > 60 mL/min: 0.15 mg/kg/hr 
CrCl 30-60 mL/min: 0.08 mg/kg/hr 
CrCl < 30 mL/min: 0.04 mg/kg/hr 
CRRT: 0.03-0.07 mg/kg/hr 
Titration Not titrated or per orders Per protocol 
Max Rate 1.75 mg/kg/hr 
0.3 mg/kg/hr without checking for 
coagulation abnormalities 
Eptifibatide (Integrilin®) 
• MOA: GP 2b3a inhibitor 
• Indication: antiplatelet for ACS or PCI 
• Contraindicated: SCr > 4 or on dialysis (don’t use CrCl in computer 
b/c have to use ABW) 
• Before PCI, concomitant heparin or enoxaparin recommended (not 
usually after) 
• DO give with aspirin and a P2Y12 (clopidogrel, prasugrel) 
• WATCH for: S/S bleeding, platelet count  
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Concentration Premix 75 mg/100 mL 
Bolus dose 180 mcg/kg, not adjusted based on renal function (max 22.6 mg) over 1-2 minutes 
Starting dose CrCl > 50 mL/min: 2 mcg/kg/min 
CrCl <= 50 mL/min or SCr 2-4:  1 mcg/kg/min  
Titration Not titrated.  Continue until discharge, CABG, or up to 72 hours  (total infusion time 
<96 hours) 
Max Rate CrCl > 50 mL/min: 15 mg/hr 
CrCl <= 50 mL/min or SCr 2-4: 7.5 mg/hr 
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Application 
• After receiving the two stents, LT is 
admitted to the ICU. 




• You want to start a norepinephrine drip on 
a 60 kg female at 0.2 mcg/kg/min using 
the standard concentration (4 mg/250 mL). 
• How many mcg/min is that? 





0.2 mcg x 60 kg = 12 mcg 
    kg      min 
 
Calculate mL/hr 
12 mcg x _1 mg__= 0.012 mg 
  min     1000 mcg     min 
 
0.012 mg x 60 min x 250 mL = 45 mL 
     min         hour        4 mg        hour 
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For More Information 
82 
Person Number 
Critical Care Pharmacy Specialist: Cheri Walker  1-1398 
Infectious Diseases Pharmacy Specialist: Ann Nguyen  6-7258 
Cardiology Pharmacy Specialist: Kristin Montarella 1-1331 
ICU mobile pharmacist 1-1401 
Central pharmacy  6-7255 
IV room 6-7261 
